An illustration of advanced spaceflight biotechnology research was performed onboard NASA’s STS-107 Columbia Shuttle mission that was tragically lost on its return from space. This project was developed by our team leader in tissue engineering, Dr. Thomas J. Goodwin in collaboration with Dr. Lelund W.K. Chung, PhD, of Cedars-Sinai, Los Angeles. This was a prostate carcinoma/bone stromal experiment that resulted in the largest tumor assemblies ever grown in microgravity.
While the experiment was lost with the Columbia shuttle, the video (Video Credit: NASA) and metabolomic data transmitted by Payload Commander Michael Anderson during the experiment, revealed this as a significant milestone in 3-dimensional (3-D) tissue biology, as reported in the Journal of the National Cancer Institute https://academic.oup.com/jnci/article/95/7/505/2520676
The space shuttle Columbia, shown here (Image Credit: NASA) after its first orbital mission in 1981, broke apart on reentry after 16 days in space on February 1, 2003 . All seven crew members were killed. One of the 80 scientific experiments on board was a project designed to recreate the natural environment in which prostate tumors develop in the presence of bone, as described above.
Please ask us about our services in spaceflight biotechnology experimental design, which includes linking the human clinical or performance question to the appropriate cellular or tissue model. Our service also includes payload integration, integrated omics analysis (genome, transcriptome, proteome, metabolome, tissue/cell phenotype), computational biology, interpretation of biological meaning, identification of potential countermeasure targets, and translation to experimental design of human studies.
For more information on Dr. Tom Goodwin’s previous NASA research see: